In the past two years, the food and drug administration has approved two novel alzheimer’s therapies, based on data from clinical trials showing that both drugs Slowed the Prograsion of the Disease. But While The Approvals of Lecanemab and Donanemab, Both Antibody Therapies That Clear Plaque-Causing Amyloid Proteins from the Brain, WiTed With Enthusiaasm by Shece ents has been muted.

According to physicians who care for people with alzheimer’s, many patients meant for their own lives.

Researchers at washington university school of medicine in st. Louis has devised a way to communicate the effects of taking the new alzheimer’s medicines in language that is accessible and undressable to patients and their families.

Using Data on the Natural History of the Disease and The Drugs ‘Effects as Measured in Clinical Trials, The Researchers Calculated How many Months of Independent Living An alzheime’ in by undergoing treatment. The Benefits Depended on the Drug and the Severity of the Patient’s Symptoms at the Time Treatment Began.

As a representative example, a typical patient who started with treatment with very mild symptoms bill expect to live independently for an additional 10 months IF TREATED WITH LACHANMAB, Or EIGT MONTH DOTH DOTH DOTHE DONS

The study, published Feb. 13 in Alzheimer’s & Dementia: Translational Research & Clinical InterventionsProvides Crucial information that can help patients and caregivers weight the benefits against the costs and risks of treatment.

“What we want to do was figure out how to give people a Piece of information that would be meaningful to them and help them make decisions about their care,” Said Senior Sarah Hartz, MD, PH.D., PH.D. Psychiatry at washu medicine.

“What people want to know is how long they will be able to live independent

Alzheimer’s Patients and their Families Are Facted With The Tough Question of Whether to Undergo a treatment that will not make them better. It Won’T even stop them from getting WorsE.

At Best, Treatment with Lecanemab Or Donanemab Block Slow The Inevitable Cognitive Decline that Characterizes Alzheimer’s. Add to this the facts that treatment is expected, requires biweekly or monthly infusions, and carries risks such as brain bleeds and brain swelling that are used Fe-threatening.

But just because the benefits are limited doesn’t mean they are not valuable to patients and their families.

“My Patients Want to Know, ‘How long can I drive? .D.

“The question of whiter or not these drugs would be helps for any particular person is complicated and has to do with not only medical factories, but the patient’s priorities, preferencies and risk teams.”

Living independently with alzheimer’s disease

There are two critical infection points on the Continuum Between Independence and Dependency. The first is the point where a person can no longer live indexantly because of an impaired ability to manage everyday tasks such as preparaing meals, driving, paying bells and reembering applications.

The second point come when a person can no longer care for his or her own body, and requires assistance with bathing, dressing and toileting.

To calculate the effects of treatment, hartz and her collegues first estimated when people could expect to lose each of the two kinds of independence if independence if left left. They are analyzed the experiences of 282 people who will participate in research study at washu medicine’s charles F. and joanne Knight Alzhese Research Center.

All participants met the criteria for treatment with the two new drugs, but hadn’t received them previous. The Researchers also called how Quickly Symptly Symptoms Progressed Without Treatment.

Using these Data on Independence and Progression, Combined with the Reported Effects of the Two Drugs, The Researchers Calculated The Amount of Time A Person at Each Stage of the Disease Counter or Themselves Independently with Treatment, and how this program Would compare to those who received treatment.

A Typical Person with very Mild Symptoms Blad Expect to live independent

Most People with Mild Symptoms – AS OPPOSED TO VERE MILD SYMPTOMS – WERE ALAREADY Unable to Live Independent .

The researchers called a typical person at this stage of the disease could expect to manage self-care independently for an additional 26 months if treated with lecanemab, 19 months with donanemab.

This way of undersrstanding the effects of the Drugs could help patients and their familyies make decisions about their care, the authors said.

“The purpose of this study is not to Advocate for or against these medicines,” Hartz Said. “The purpose of the paper is to put the impact of these medicines into context in ways that can help people make the decisions that are best for themeselves and their family members.”